PF-Atlas › Treatments › Lipofibroblast Niche Restoration

Lipofibroblast Niche Restoration

PPAR-y agonist + FGF10 restores AEC2 metabolic support niche

Clinical research — In human clinical trials (Phase I–III). How PF-Atlas grades evidence.
Development stage
Preclinical
Evidence level
Level 3 (Preclinical)
Mechanism class
PPAR-y agonist + FGF10 restores AEC2 metabolic support niche
Timeline
2-4 years
Risk profile
Low
Developer
Multiple
Key researchers
E. El Agha

Overview

Lipofibroblasts replaced by myofibroblasts in IPF. PPAR-y agonists (pioglitazone) reverse this. FGF10 rebuilds MANC niche.

How Lipofibroblast Niche Restoration fits into IPF treatment

Lipofibroblast Niche Restoration is classified as Level 3 (Preclinical) at the Preclinical stage. Explore how it compares to other options and where it sits in the development pipeline:

Lipofibroblast Niche Restoration drug profilePPAR-y agonist + FGF10 restores AEC2 metabolic support nicheClinical trialsDrug pipelineResearch

Other IPF treatments

Nerandomilast / JascaydInhaled Treprostinil / TyvasoAdmilparant / BMS-986278Rentosertib / ISM001-055AI Knowledge GraphuPAR-CAR-T Senolytic Immunotherapy
Medical disclaimer. This page summarizes published research and PF-Atlas model output about Lipofibroblast Niche Restoration for information only. It is not medical advice or a treatment recommendation. Drug availability, approval status and evidence change — verify with a pulmonologist and official sources (FDA, ClinicalTrials.gov) before any decision.